Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for prevention of acute and delayed nausea and vomiting during high-dose cyclophosphamide for PBSC harvesting
2009-017603-28Phase 3Active
- Sponsor
- Azienda Ospedaliera di Perugia
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Aprepitant + palonosetron + dexamethasone with Placebo + palonosetron + dexamethasone (2 arms). Primary endpoint: Complete response rate. Started Jan 2010; status: active.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2009-017603-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017603-28.